JP2022505679A5 - - Google Patents

Info

Publication number
JP2022505679A5
JP2022505679A5 JP2021522096A JP2021522096A JP2022505679A5 JP 2022505679 A5 JP2022505679 A5 JP 2022505679A5 JP 2021522096 A JP2021522096 A JP 2021522096A JP 2021522096 A JP2021522096 A JP 2021522096A JP 2022505679 A5 JP2022505679 A5 JP 2022505679A5
Authority
JP
Japan
Prior art keywords
chain variable
amino acid
variable domain
tcr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505679A (ja
JP7569313B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057543 external-priority patent/WO2020086647A1/en
Publication of JP2022505679A publication Critical patent/JP2022505679A/ja
Publication of JP2022505679A5 publication Critical patent/JP2022505679A5/ja
Application granted granted Critical
Publication of JP7569313B2 publication Critical patent/JP7569313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522096A 2018-10-23 2019-10-23 Ny-eso-1 t細胞受容体およびそれらの使用の方法 Active JP7569313B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749194P 2018-10-23 2018-10-23
US62/749,194 2018-10-23
PCT/US2019/057543 WO2020086647A1 (en) 2018-10-23 2019-10-23 Ny-eso-1 t cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022505679A JP2022505679A (ja) 2022-01-14
JP2022505679A5 true JP2022505679A5 (https=) 2022-10-31
JP7569313B2 JP7569313B2 (ja) 2024-10-17

Family

ID=68582342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522096A Active JP7569313B2 (ja) 2018-10-23 2019-10-23 Ny-eso-1 t細胞受容体およびそれらの使用の方法

Country Status (10)

Country Link
US (1) US12466870B2 (https=)
EP (1) EP3870602A1 (https=)
JP (1) JP7569313B2 (https=)
KR (1) KR102933479B1 (https=)
CN (1) CN113454110B (https=)
AU (2) AU2019364367B2 (https=)
CA (1) CA3117539A1 (https=)
EA (1) EA202191107A1 (https=)
MA (1) MA53981A (https=)
WO (1) WO2020086647A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
WO2020086647A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP7526079B2 (ja) * 2020-11-13 2024-07-31 Ykk Ap株式会社 樹脂枠の製造方法、樹脂枠
TW202246511A (zh) * 2021-02-25 2022-12-01 美商萊爾免疫藥物股份有限公司 靶向ny-eso-1之增強免疫細胞療法
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN113912701B (zh) * 2021-10-14 2024-07-19 深圳大学总医院 Tcr及其在诊断/治疗中的应用
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ, インコーポレイテッド Cd73化合物
EP4449418A4 (en) * 2021-12-15 2025-11-19 3T Biosciences Inc METHODS AND SYSTEMS FOR EVALUATING IMMUNE CELL RECEPTORS AND ANTIGENS
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
US12584107B2 (en) 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230287080A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2852613B1 (en) * 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
EP3404111A1 (en) 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
AU2014301777B2 (en) 2013-06-26 2017-03-30 Xlifesc, Ltd. High-stability T-cell receptor and preparation method and application thereof
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
CN105985427A (zh) * 2015-02-06 2016-10-05 广州市香雪制药股份有限公司 高亲和力ny-eso t细胞受体
EP4248744A3 (en) 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
CN106188275A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的t细胞受体
US20190119350A1 (en) * 2015-09-09 2019-04-25 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
CN106432475B (zh) * 2015-10-19 2018-06-01 广东香雪精准医疗技术有限公司 高亲和力ny-eso t细胞受体
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
JP2020503883A (ja) * 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ny−eso−1に結合するt細胞受容体およびその使用方法
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途
WO2020086647A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022505679A5 (https=)
JP2022537359A5 (https=)
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
JP2022141910A (ja) 抗tigit抗体
JP2022527635A5 (https=)
JP2016527286A5 (https=)
JP2020501531A5 (https=)
JP2022518925A5 (https=)
JP2020036595A (ja) 抗ヒト4−1bb抗体およびその使用
JP2023511417A5 (https=)
JP2020527144A5 (https=)
JP2013527761A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
RU2019138067A (ru) Биспецифическое антитело против ox40 и ctla-4
JP2021508255A5 (https=)
KR20170067732A (ko) 림프구에서의 억제 경로의 중화
JP2017515792A5 (https=)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2022538475A5 (https=)
CN114729053B (zh) 一种4-1bb结合蛋白及其应用
JP2021512637A5 (https=)
JP2023530036A5 (https=)
JP2023530037A5 (https=)
JP2022521956A5 (https=)
JP2022527084A5 (https=)